Shares of clinical-stage biopharmaceutical company Verona Pharma (NASDAQ:VRNA) are soaring in morning trading today after the company announced positive data from the Phase 3 trial of nebulized ensifentrine as a maintenance treatment for the chronic obstructive pulmonary disease (COPD).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The study achieved primary as well as key secondary endpoints indicating improvement in lung function, symptoms as well as measures of quality of life in patients.
Importantly, the company now plans to submit a New Drug Application for the treatment in H1 2023.
Verona shares have now jumped nearly 250% over the past six months.
Read full Disclosure
